


**Product Name** : R428  
**Cat. No.** : PC-20336  
**CAS No.** : 1037624-75-1  
**Molecular Formula** : C<sub>30</sub>H<sub>34</sub>N<sub>8</sub>  
**Molecular Weight** : 506.66  
**Target** : TAM Receptor (Tyro3-Axl-Mer)  
**Solubility** : 10 mM in DMSO



## Biological Activity

R428 (Bemcentinib, BGB324) is potent, selective and orally bioavailable inhibitor of Axl kinase with IC<sub>50</sub> of 14 nM.

R428 inhibits phosphorylation of Akt (Ser473) and Axl (Tyr821) in cell-based activity assays.

R428 exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells.

R428 is >100-fold selective for Axl over insulin receptor, EGFR, HER2, and PDGFR $\beta$  and kinases of other subfamilies.

R428 (0-3  $\mu$ M) dose dependently suppresses invasion of both human MDA-MB-231 and murine 4T1 breast cancer cell lines.

R428 (125 mg/kg, BID) suppresses breast cancer metastasis in MDA-MB-231 xenograft and orthotopic 4T1 models.

R428 suppresses angiogenesis in vivo and modulates expression of surrogate markers in tumor tissue.

## References

Holland SJ, et al. Cancer Res. 2010 Feb 15;70(4):1544-54.

Hector A, et al. Cancer Biol Ther. 2010 Nov 15;10(10):1009-18.

Lijnen HR, et al. J Pharmacol Exp Ther. 2011 May;337(2):457-64.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com